Fever is an important early sign of serious treatment-related adverse events such as cytokine release syndrome (CRS) caused by chimeric antigen receptor T cell (CAR-T) immunotherapy and such as infection related to chemotherapy induced neutropenia
(Oved, Barrett and Teachey, 2019; Freifeld et al., 2011), both events that are commonly experienced by patients with cancer.
The standard approach for detecting fever in hospitalized patients is intermittent temperature monitoring, typically every 4–8 h; this could lead to inherent delays in diagnosis of febrile adverse events.
The availability of non-invasive, wireless, wearable sensors to continuously monitor body temperature raises the possibility of earlier detection and diagnosis of fever and its associated adverse events. Some studies have begun to investigate this possibility (Jordan et al., 2017; Sampson et al., 2019; Liu et al., 2020; Smarr et al., 2020), yet a systematic investigation in patients with cancer performed with FDA-approved devices and compared to standard-of-care (SOC) monitoring is needed. Furthermore, the large volume of high-frequency temperature data that can be obtained from a wearable sensor opens the possibility of carrying out computational analysis to identify signals for anticipating fever before it occurs.
To read more, please click here.